Gritstone Oncology – $100 Million IPO

Cooley advised the underwriters on Gritstone Oncology, Inc.'s $100 million initial public offering of 6,666,667 shares of common stock. The underwriters have a 30-day option to purchase an additional 1,000,000 shares. Partners Dave Peinsipp, Drew Williamson and Charlie Kim led the Cooley team advising the underwriters.

Goldman Sachs & Co. LLC, Cowen and Barclays acted as joint book-running managers for the offering. BTIG acted as a lead manager.

Gristone Oncology is an immuno-oncology company developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company’s shares now trade on the Nasdaq Global Select Market under the symbol “GRTS.”


Related Contacts
David Peinsipp Partner, San Francisco
Drew Williamson Partner, San Francisco
Charlie Kim Partner, San Diego
Kristin VanderPas Partner, San Francisco
Denny Won Associate, San Francisco
Christopher Wong Associate, San Francisco
Related Practices & Industries

Capital Markets Public Companies Life Sciences